Dr. van den Bent on Next Steps for ABT-414 in Brain Cancer
Martin J. van den Bent, MD, ‎Head Neuro-Oncology Unit at Erasmus MC Cancer Center, discusses what the next trials will be for ABT-414, anti-EGFR antibody-drug conjugate under exploration for patients with brain cancer.
Martin J. van den Bent, MD, ‎Head Neuro-Oncology Unit at Erasmus MC Cancer Center, discusses what the next trials will be for ABT-414, anti-EGFR antibody-drug conjugate under exploration for patients with brain cancer.
In an expansion cohort of a phase I study, patients with EGFR-amplified, recurrent glioblastoma (GBM) who were treated with ABT-414 experienced a 6-month progression-free survival (PFS) rate of 35%. While this trial was a phase I expansion trial, van den Bent notes, the results proved that further investigation was warranted.
There is currently an ongoing phase II trial exploring ABT-414 alone or with temozolomide in comparison with lomustine or temozolomide for patients with recurrent GBM. This study will include a pediatric arm focused on adverse events (NCT02343406). The primary endpoints for the adult arm of the study, which is known as INTELLANCE 2, are PFS and overall survival (OS).
Additionally, a phase II study is exploring the frontline use of ABT-414 for patients with newly-diagnosed GBM (NCT02573324). This trial, INTELLANCE 1, has dual primary endpoints of PFS and OS.
These studies will provide more data to understand which patients respond well to ABT-414 and which would be resistant to the compound, van den Bent noted.
<<<
